Piperacillin-induced seizures

Clinical Pediatrics

Volumn 36, Issue 8, 1997, Pages 475-478

  Malanga, C J ^a   Kokontis, Lisa ^a   Mauzy, Susan ^a   Bodensteiner, John B ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; MERCAPTOPURINE; METHOTREXATE; PHENYTOIN; PIPERACILLIN; TOBRAMYCIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CASE REPORT; CHILD; DRUG INDUCED DISEASE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; SEIZURE; TONIC CLONIC SEIZURE; URINARY TRACT INFECTION;

EID: 0030791758     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992289703600807     Document Type: Article

References (20)

1. Thomas RJ. Neurotoxicity of antibacterial therapy. South Med J. 1994;87: 869-874.
2. Barrons RW, Murray KM, Richey RM. Populations at risk for penicillin-induced seizures. Ann Pharmacother. 1992;26:26-29.
3. Zaccara G, Muscas GC, Messori A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Safety. 1990;5:109-151.
4. Piperacillin sodium. Medical Letter. 1982;24:48-49.
5. Mackie K, Pavlin EG. Recurrent paralysis following piperacillin administration. Anesthesiology. 1990;72:561-563.
6. Fortner CL, Finley RS, Schimpff SC. Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Pharmacotherapy. 1982;2:287-299.
7. Wise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. J Antimicrob Chemother. 1993;31(Suppl. A):97-104.
8. Kuye O, Teal J, DeVries VG, et al. Safety profile of piperacillin/tazobactam in phase I and III clinical studies. J Antimicrob Chemother. 1993;31 (Suppl. A):113-124.
9. Dickinson GM, Droller DG, Greenman RL, et al. Clinical evaluation of piperacillin with observations on penetrability into cerebrospinal fluid. Antimicrob Agents Chemother. 1981;20:481-486.
10. Eng RH, Munsif AN, Yangco BG, et al. Seizure propensity with imipenem. Arch Intern Med. 1989;149:1881-1883.
11. Malone JD, Lebar RD, Hilder R. Procaine-induced seizures after intramuscular procaine penicillin G. Mil Med. 1988;153:191-192.
12. Asensi F, Otero MC, Perez-Tamarit D, et al. Risk/benefit in the treatment of children with imipenem-cilastin for meningitis caused by penicillin-resistant pneumococcus. J Chemother. 1993; 5:133-134.
13. Keskin S, Konkol RJ. Seizure exacerbation related to beta-lactam antibiotics in a child with cerebral dysgenesis. Dev Med Child Neurol. 1993;35: 267-274.
14. Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastin treatment of bacterial meningitis in children. Pediatr Infect Dis J. 1991;10:122-125.
15. Jalbert EO. Seizures after penicillin administration [letter]. Am J Dis Child. 1985;139:1075.
16. Silber TJ, D'Angelo L. Psychosis and seizures following the injection of penicillin G procaine. Hoigne's syndrome. Am J Dis Child. 1985;139:335-337.
17. Reid KH, Shields CB, Raff MJ, et al. Effect of the topical application of some newer antibiotics on the cerebral cortex. Neurosurgery. 1987;20: 868-870.
18. De Sarro A, Ammendola D, Zappala M, et al. Relationship between structure and convulsant properties of some β-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother. 1995;39:232-237.
19. Kellaway P. Sleep and epilepsy. Epilepsia. 1985;26(Suppl. 1):S15-S30.
20. Norrby SR. Problems in evaluation of adverse reactions to β-lactam antibiotics. Rev Infect Dis. 1986;8(Suppl. 3): S358-S370.